RETSEVMO caps 40 mg 56 pce
7680678620040
CH-67862
L01EX22
07.16.1.
Reimbursement limitations:
RETSEVMO2.2L
2L NSCLC
Après garantie de prise en charge des coûts par l'assureur-maladie après consultation préalable …
1 / 3
google
Details
- Product number
- 6786201
- CPT
- -
- Packaging group
- 56
- Unit
- Kapsel(n)
- Composition
- Capsule: selpercatinibum 40 mg, cellulosum microcristallinum, silica colloidalis anhydrica, matériel de la capsule: gelatina, E 171, E 172 (nigrum), encre: lacca, propylenglycolum, kalii hydroxidum, E 172 (nigrum), pro capsula.
Articles (1)
Retsevmo 40 mg, gélules
Kapseln
56
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
CAP
|
40.0 MG | Substance | Wirkstoff (Principe actif) |
|
CAP
|
- | Substance | HNIDK |
|
CAP
|
- | Substance | HNIDK |
|
CAP
|
- | Substance | HNIDK |
|
CAP
|
- | Substance | FNIDK |
|
CAP
|
- | Substance | FTODK |
|
CAP
|
- | Substance | HNIDK |
|
CAP
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
CAP
|
- | Substance | HNIDK |
|
CAP
|
- | Substance | FTODK |
Reimbursement information
Public price
CHF 2146.80
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/03/2022
Authorization holder
Eli Lilly (Suisse) SA
1214 Vernier
Authorization information
- Swissmedic authorization number
- 67862
- Drug name
- Retsevmo, gélules
- Galenic form
- KAHA
- ATC Code
- L01EX22
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 08/02/2021
- Authorization expiration date
- 19/12/2029
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- RETSEVMO caps 40 mg 56 pce
- Description (DE)
- RETSEVMO Kaps 40 mg 56 Stk
- Market launch
- 08/02/2021
- Narcotic (BTM)
- No